Europe — EMA

Ondansetron B. Braun

Ondondansetron, the active ingredient in Ondansetron B. Braun, is a 5-HT3 receptor antagonist presented as a unknown/unknown for intramuscular, intravenous use.

Ondansetron

Request sourcing

Pack/s

What is Ondansetron?

Ondondansetron, the active ingredient in Ondansetron B. Braun, is a 5-HT3 receptor antagonist presented as a unknown/unknown for intramuscular, intravenous use. It treats and prevents nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative settings in patients requiring antiemetic therapy.

GNH USA supplies Ondansetron B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

What is Ondansetron used for?

Ondansetron B. Braun is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting pathways:

- Chemotherapy‑induced nausea and vomiting: Helps prevent the onset of nausea and vomiting associated with cytotoxic chemotherapy. - Radiotherapy‑induced nausea and vomiting: Reduces the frequency of vomiting during or after radiation treatment. - Post‑operative nausea and vomiting: Decreases the incidence of vomiting after surgical procedures. - Pregnancy ? ??? - ??? - …

What are the side effects of Ondansetron?

Common

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →